Mindera is a Rosenman Innovator company.
From the press release.
Mindera Corporation today announced a $12.6M Series A-2 capital raise. The round was led by Mountain Group Partners, Rockmont Investments, and Scientific Health Development. The funding will be used to commercialize Mind.Px, a groundbreaking tool to prospectively predict patient response to expensive psoriasis biologics, as well as continue development of the Mindera Dermal Intelligence™ Platform.
The Mindera platform uses a simple patch that extracts biomarkers from the skin in minutes, allowing for rapid and painless extraction of RNA. Subsequent Next-Generation Sequencing of the extracted RNA allows Mindera scientists to take a genetic and transcriptomic snapshot of the skin at the exact moment of the test. In the case of Mind.Px, this rich patient-specific data is then analyzed by proprietary machine learning algorithms to predict the appropriate psoriasis biologic drug for a patient prior to therapeutic selection and treatment.
Mind.Px is a first-of-its-kind precision medicine dermatology solution that aligns patient, physician, and payer interests by predicting effective biologics for individuals, avoiding trial-and-error prescription behavior and wasted payer spending.
For more information, contact firstname.lastname@example.org.
Mindera is a private San Diego-area company developing and commercializing next-generation medical technology to enable a new era of skin analytics at the molecular level. Using a proprietary dermal biomarker patch, Next-Generation Sequencing (NGS) and Machine Learning, Mindera technology generates clinically validated data to reduce healthcare system costs and improve patient outcomes. Mindera is a CLIA and ISO 13485 certified Laboratory. Find out more at www.minderadx.com.